SKP2 and cancer: Various Skp2 inhibiting compounds have been developed to inhibit the degradation of p27 mediated by Skp2 for cancer treatment, such as Skp2E3LIs (Wu L. et al., 2012), and the p27 protein level was taken as a point for selecting Skp2 inhibiting compound, such as when screening SMIP004 (Rico-Bautista et al., 2010).